S 272
· 119th Congress
· Health
Protect Infant Formula from Contamination Act
Sponsor
Latest action
Message on Senate action sent to the House.
Action timeline
Every recorded action on this bill, newest first. Stage badges color-code the legislative path.
May 04, 2026
floor
Received in the House.
May 04, 2026
floor
Held at the desk.
May 01, 2026
floor
Message on Senate action sent to the House.
Apr 28, 2026
passed
Passed/agreed to in Senate: Passed Senate with an amendment and an amendment to the Title by Unanimous Consent.
Apr 28, 2026
passed
Passed Senate with an amendment and an amendment to the Title by Unanimous Consent. (consideration: CR S2074-2075; text: CR S2074)
Jan 28, 2026
committee
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute and an amendment to the title. Without written report.
Health, Education, Labor, and Pensions Committee
Jan 28, 2026
other
Placed on Senate Legislative Calendar under General Orders. Calendar No. 306.
Jan 15, 2026
committee
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Health, Education, Labor, and Pensions Committee
Jan 28, 2025
introduced
Introduced in Senate
Jan 28, 2025
introduced
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee
Text versions
Each stage of the bill — official text published by GPO. Click any format to read on congress.gov / govinfo.
CRS summaries
Plain-English summaries written by the Congressional Research Service — neutral, nonpartisan staff who summarize bills as they advance through stages. The authoritative description of what each version of the bill does.
00
Introduced in Senate
Jan 28, 2025
Protect Infant Formula from Contamination Act
This bill imposes certain new requirements on infant formula manufacturers and the Food and Drug Administration (FDA) following the discovery of contaminated, adulterated, or misbranded infant formula.
Specifically, the bill requires infant formula manufacturers to report to the FDA within one business day of learning that formula that was processed by the manufacturer but that is no longer within the manufacturer’s control may not provide required nutrients or may be otherwise adulterated or misbranded.
Further, if any testing of finished infant formula reveals the presence of specified microorganisms (e.g., salmonella), the manufacturer must notify the FDA within one business day. (Under current law, manufacturers are only required to report contamination to the FDA if the affected formula has left the manufacturer’s control.) The manufacturer must also promptly provide the test results to the FDA and consult with the FDA on proper isolation and disposal of the affected product. The FDA must respond to such a notification and begin discussing proper investigative and corrective action with the manufacturer within one business day.
Within 90 days of a report of adulterated, misbranded, or contaminated infant formula, the FDA must determine whether the manufacturer that reported the problem has performed, or is performing, appropriate investigative and corrective action.
Finally, the FDA is required to periodically report on the infant formula supply chain and efforts to improve the safety and supply of infant formula, and must consult with other federal agencies and infant formula stakeholders on these issues.
via Congressional Research Service · published through congress.gov
Changelog
ⓘ
How a bill moves through Congress. Each stage produces a new official text. The diff between them shows what changed at that step.
ih / is — Introduced in House / Senate. First filed version.rfh / rfs — Referred to a committee for review.rh / rs — Reported back by the committee to the floor (often with amendments — this is where most language changes happen).pcs / pch — Placed on Calendar for floor consideration.eh / es — Engrossed. Passed by the originating chamber. Text is now what was actually voted on.rdh / rds — Received by the other chamber.eah / eas — Engrossed Amendment. The other chamber passed an amended version.ath / ats — Agreed to. Both chambers settled on the same text.enr — Enrolled. Final reconciled text, sent to the President.pl — Public Law. Signed by the President. It's now law.pp — Public Print. Official printing post-enactment.
Most bills die before eh/es. Going from pcs → enr is the full path through both chambers.
ⓘ
How a bill moves through Congress. Each stage produces a new official text. The diff between them shows what changed at that step.
ih/is— Introduced in House / Senate. First filed version.rfh/rfs— Referred to a committee for review.rh/rs— Reported back by the committee to the floor (often with amendments — this is where most language changes happen).pcs/pch— Placed on Calendar for floor consideration.eh/es— Engrossed. Passed by the originating chamber. Text is now what was actually voted on.rdh/rds— Received by the other chamber.eah/eas— Engrossed Amendment. The other chamber passed an amended version.ath/ats— Agreed to. Both chambers settled on the same text.enr— Enrolled. Final reconciled text, sent to the President.pl— Public Law. Signed by the President. It's now law.pp— Public Print. Official printing post-enactment.
Most bills die before eh/es. Going from pcs → enr is the full path through both chambers.
Line-level diff between text versions of this bill — what actually changed at each legislative stage.
+10
−159
30 unchanged
--- Reported (Senate)
+++ Engrossed (Senate)
@@ -1,165 +1,21 @@
[From the U.S. Government Publishing Office]
-[S. 272 Reported in Senate (RS)]
+[S. 272 Engrossed in Senate (ES)]
<DOC>
-Calendar No. 306
119th CONGRESS
2d Session
S. 272
-To improve the safety of infant formula through testing of infant
-formula for microorganisms and toxic elements, and for other purposes.
-
_______________________________________________________________________
-IN THE SENATE OF THE UNITED STATES
-
-January 28, 2025
-
-Mr. Peters (for himself, Mr. Hoeven, Ms. Collins, Ms. Smith, Mrs.
-Shaheen, Ms. Hassan, Mr. Kaine, and Ms. Baldwin) introduced the
-following bill; which was read twice and referred to the Committee on
-Health, Education, Labor, and Pensions
-
-January 28, 2026
-
-Reported by Mr. Cassidy, with an amendment and an amendment to the
-title
-[Strike out all after the enacting clause and insert the part printed
-in italic]
-
-_______________________________________________________________________
-
-A BILL
+AN ACT
To improve the safety of infant formula through testing of infant
-formula for microorganisms and toxic elements, and for other purposes.
+formula for microorganisms, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
-
-<DELETED>SECTION 1. SHORT TITLE.</DELETED>
-
-<DELETED> This Act may be cited as the ``Protect Infant Formula from
-Contamination Act''.</DELETED>
-
-<DELETED>SEC. 2. NOTIFICATIONS FOR TESTING OF INFANT FORMULA.</DELETED>
-
-<DELETED> Section 412(e) of the Federal Food, Drug, and Cosmetic Act
-(21 U.S.C. 350a(e)) is amended--</DELETED>
-<DELETED> (1) in paragraph (1), in the matter following
-subparagraph (B)--</DELETED>
-<DELETED> (A) by striking ``promptly'';</DELETED>
-<DELETED> (B) by inserting ``, within 1 business day
-of acquiring such knowledge'' after ``such knowledge'';
-and</DELETED>
-<DELETED> (C) by striking ``the infant formula'' and
-inserting ``an infant formula'';</DELETED>
-<DELETED> (2) by redesignating paragraph (2) as paragraph
-(5); and</DELETED>
-<DELETED> (3) by inserting after paragraph (1) the
-following:</DELETED>
-<DELETED> ``(2) If the result of any testing of a sample from any
-production aggregate of finished infant formula product is confirmed as
-a positive analytical result for any microorganism for which finished
-product testing is required under section 106.55(e) of title 21, Code
-of Federal Regulations (or any successor regulation), the manufacturer
-shall--</DELETED>
-<DELETED> ``(A) within 1 business day of acquiring a
-confirmed positive analytical result, notify the Secretary of
-such result, regardless of whether such product has left an
-establishment subject to the control of the
-manufacturer;</DELETED>
-<DELETED> ``(B) promptly consult with the Secretary for
-proper isolation of the affected product, and, as the Secretary
-may require, cease distribution and properly dispose of the
-affected product; and</DELETED>
-<DELETED> ``(C) promptly provide to the Secretary results
-and isolates from a positive sample of such product or the
-whole genetic sequence from any confirmed positive analytical
-result.</DELETED>
-<DELETED> ``(3) Not later than 1 business day after receipt by the
-Secretary of a notification under paragraph (2)(A), the Secretary shall
-respond to the manufacturer of the infant formula to begin discussions
-regarding investigation and corrective action, and, as appropriate,
-share the findings of the Secretary with the manufacturer.</DELETED>
-<DELETED> ``(4) Not later than 90 days after receipt of a
-notification under paragraph (1) or (2), the Secretary shall confirm,
-including through the collection of documentation, that the
-manufacturer submitting the notification performed, or is performing,
-an appropriate investigation and corrective action, if applicable. The
-Secretary shall consider, as part of the review of the root cause
-investigation, the analytical method used to conduct laboratory testing
-and, as appropriate, the potential for cross contamination of the
-sample by handling and testing. The manufacturer shall make such
-documentation available to the Secretary electronically and for
-inspection under section 704.''.</DELETED>
-
-<DELETED>SEC. 3. REPORTING TO IMPROVE THE SAFETY AND SUPPLY OF INFANT
-FORMULA.</DELETED>
-
-<DELETED> Section 412 of the Federal Food, Drug, and Cosmetic Act
-(21 U.S.C. 350a) is amended by adding at the end the
-following:</DELETED>
-<DELETED> ``(n) Reporting To Improve the Safety and Supply of Infant
-Formula.--</DELETED>
-<DELETED> ``(1) Progress report.--Not later than 180 days
-after the date of enactment of the Protect Infant Formula from
-Contamination Act, the Secretary shall issue a progress report
-on implementation of the recommendations to improve the safety
-and supply of infant formula contained in the report titled,
-`Long-Term National Strategy to Increase the Resiliency of the
-U.S. Infant Formula Market', issued by the Food and Drug
-Administration in January 2025. Such progress report shall
-include additional authorities or resources that the Secretary
-may require for purposes of improving the safety and supply of
-infant formula.</DELETED>
-<DELETED> ``(2) Quarterly reports on supply chain.--Not
-later than 270 days after the date of enactment of the Protect
-Infant Formula from Contamination Act, and not less frequently
-than quarterly for the 5-year period thereafter, the Secretary
-shall submit a report on the most current, critical supply
-chain data for infant formula, including in-stock rates, to--
-</DELETED>
-<DELETED> ``(A) the Committee on Health, Education,
-Labor, and Pensions; the Committee on Agriculture,
-Nutrition, and Forestry; and the Subcommittee on
-Agriculture, Rural Development, Food and Drug
-Administration, and Related Agencies of the Committee
-on Appropriations of the Senate; and</DELETED>
-<DELETED> ``(B) the Committee on Energy and
-Commerce; the Committee on Agriculture; and the
-Subcommittee on Agriculture, Rural Development, Food
-and Drug Administration, and Related Agencies of the
-Committee on Appropriations of the House of
-Representatives.</DELETED>
-<DELETED> ``(3) Consultation.--The Secretary shall engage
-with the Department of Agriculture and other relevant agencies
-of the Federal Government regarding ongoing efforts to address
-immediate formula needs and build long-term resiliency into the
-infant formula market.</DELETED>
-<DELETED> ``(4) Reports on adequacy of supply.--Not later
-than 1 year, 3 years, and 5 years after the date of enactment
-of the Protect Infant Formula from Contamination Act, the
-Secretary shall--</DELETED>
-<DELETED> ``(A) engage with public stakeholders,
-infant formula manufacturers, and other stakeholders,
-as determined by the Secretary, to determine evidence-
-based practices that can be implemented to maximize
-infant formula supply and infant safety, which may
-include the value of high frequency testing for
-purposes of identifying contamination events and
-bracketing potentially contaminated product, the impact
-of corrective action on contamination events, and
-evidence-based recommendations for enhancing infant
-formula supply and safety; and</DELETED>
-<DELETED> ``(B) submit a report to the committees
-described in subparagraphs (A) and (B) of paragraph (2)
-that identifies the modifications to manufacturer
-practices and actions described in subparagraph (A), if
-any, that could be implemented to improve infant
-formula supply and safety.''.</DELETED>
SECTION 1. SHORT TITLE.
@@ -278,11 +134,12 @@
and actions described in subparagraph (A), if any, that
could be implemented to improve infant formula supply
and safety.''.
-Amend the title so as to read: ``A bill to improve the
-safety of infant formula through testing of infant formula for
-microorganisms, and for other purposes.''.
-Calendar No. 306
+Passed the Senate April 28, 2026.
+
+Attest:
+
+Secretary.
119th CONGRESS
2d Session
@@ -291,13 +148,7 @@
_______________________________________________________________________
-A BILL
+AN ACT
To improve the safety of infant formula through testing of infant
-formula for microorganisms and toxic elements, and for other purposes.
-
-_______________________________________________________________________
-
-January 28, 2026
-
-Reported with an amendment and an amendment to the title
+formula for microorganisms, and for other purposes.
Lobbying activity
Organizations whose LDA filings reference this bill, ranked by filing count. Position not disclosed — LDA does not require lobbyists to report support / oppose / monitor. Bill-number references can be stale (lobbyists sometimes copy text year-over-year), so verify against the filing description.
BOBBIE BABY, INC.
AGRHCR
5
filings · 2026 Q3
4
filings · 2025 Q2
1
filings · 2026 Q1
1
filings · 2026 Q1
via Senate LDA · self-reported quarterly. Filing count = filings mentioning this bill (no position required), not money spent on it. Click a client to see all bills they've filed on.
Cosponsors (9)
Members who signed on to support this bill.